Publisher Correction: Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosis.

التفاصيل البيبلوغرافية
العنوان: Publisher Correction: Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosis.
المؤلفون: Brastianos PK; Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. pbrastianos@mgh.harvard.edu., Lee EQ; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Cohen JV; Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA., Tolaney SM; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Lin NU; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Wang N; Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA., Chukwueke U; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., White MD; Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA., Nayyar N; Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA., Kim A; Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA., Alvarez-Breckenridge C; Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA., Krop I; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Mahar MK; Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA., Bertalan MS; Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA., Shaw B; Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA., Mora JL; Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA., Goss N; Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA., Subramanian M; Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA., Nayak L; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Dietrich J; Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA., Forst DA; Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA., Nahed BV; Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA., Batchelor TT; Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA., Shih HA; Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA., Gerstner ER; Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA., Moy B; Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA., Lawrence D; Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA., Giobbie-Hurder A; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Carter SL; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Oh K; Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA., Cahill DP; Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA., Sullivan RJ; Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
المصدر: Nature medicine [Nat Med] 2020 Aug; Vol. 26 (8), pp. 1309.
نوع المنشور: Published Erratum
اللغة: English
بيانات الدورية: Publisher: Nature Publishing Company Country of Publication: United States NLM ID: 9502015 Publication Model: Print Cited Medium: Internet ISSN: 1546-170X (Electronic) Linking ISSN: 10788956 NLM ISO Abbreviation: Nat Med Subsets: PubMed not MEDLINE; MEDLINE
أسماء مطبوعة: Publication: New York Ny : Nature Publishing Company
Original Publication: New York, NY : Nature Pub. Co., [1995-
مستخلص: An amendment to this paper has been published and can be accessed via a link at the top of the paper.
التعليقات: Erratum for: Nat Med. 2020 Aug;26(8):1280-1284. (PMID: 32483359)
تواريخ الأحداث: Date Created: 20200620 Latest Revision: 20210130
رمز التحديث: 20221213
DOI: 10.1038/s41591-020-0978-1
PMID: 32555425
قاعدة البيانات: MEDLINE
الوصف
تدمد:1546-170X
DOI:10.1038/s41591-020-0978-1